Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PLUR
PLUR logo

PLUR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pluri Inc (PLUR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.590
1 Day change
-0.83%
52 Week Range
7.130
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Pluri Inc (PLUR) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company's revenue and net income have shown YoY growth, the financials still indicate negative profitability, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. The technical indicators are neutral, and there is no recent news or influential trading activity to drive momentum.

Technical Analysis

The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 71.819, and moving averages are converging, indicating no clear trend. Key support and resistance levels are Pivot: 3.489, R1: 3.737, S1: 3.24, R2: 3.89, S2: 3.087. The stock has a 40% chance to increase by 0.49% in the next day, but the weekly and monthly trends are not strongly bullish.

Positive Catalysts

  • Revenue increased by 7.03% YoY, and net income improved by 121.35% YoY, indicating some growth momentum.

Neutral/Negative Catalysts

  • No recent news, significant trading trends, or influential trading activity to act as a catalyst.

Financial Performance

In Q2 2026, revenue increased to $198,000 (up 7.03% YoY), net income improved to -$6,543,000 (up 121.35% YoY), and EPS increased to -0.71 (up 33.96% YoY). However, gross margin dropped significantly to 43.43% (down -27.62% YoY), reflecting operational challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast PLUR stock price to rise
Analyst Rating
0
Wall Street analysts forecast PLUR stock price to rise
Buy
Hold
Sell
0
Current: 3.620
sliders
Low
0
Averages
0
High
0
0
Current: 3.620
sliders
Low
0
Averages
0
High
0
Alliance Global Partners
Matthew Venezia
initiated
$12
AI Analysis
2025-06-02
Reason
Alliance Global Partners
Matthew Venezia
Price Target
$12
AI Analysis
2025-06-02
initiated
Reason
Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri with a Buy rating and $12 price target. The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its "differentiated" bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri's bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.

People Also Watch